BIIB Maintains Rating by Morgan Stanley -- Price Target Raised to $231

Morgan Stanley has reiterated its "Equal-Weight" rating for Biogen (BIIB) and increased its price target from $222.00 to $231.00. Despite this positive adjustment, GuruFocus's GF Value™ indicates that Biogen is currently 7.2% overvalued. The company's GF Score™ of 68/100 points to strong profitability and valuation but highlights challenges in growth and momentum.